Johnson & Johnson (JNJ)

163.98
1.80 1.10
NYSE
Prev Close 165.75
Open 165.68
Day Low/High 163.31 / 165.76
52 Wk Low/High 133.65 / 179.92
Volume 7.02M
Exchange NYSE
Shares Outstanding 2632.48B
Market Cap 431.94B
P/E Ratio 28.74
Div & Yield N.A. (N.A)
Big-Cap Technology Regains Its Leadership as Banks Kick Off Earnings Season

Big-Cap Technology Regains Its Leadership as Banks Kick Off Earnings Season

There was some significant rotational action Monday and we'll see if that continues as we move into earnings reports.

Jim Cramer: Here's Why the President Is Gambling With Stimulus

Jim Cramer: Here's Why the President Is Gambling With Stimulus

The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.

Jim Cramer: You Heard the Ugly of the Debate. Here's the Good.

Jim Cramer: You Heard the Ugly of the Debate. Here's the Good.

Neither candidate seems to be the enemy of the market -- at least not yet.

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

With Q3 Earnings Up Ahead, Can Johnson & Johnson Set the Table?

I see no reason to flee this name, therefore, I am not.

Certainty of Uncertainty, Lines in the Sand, Election Fears, Fed Alone, Twitter

Certainty of Uncertainty, Lines in the Sand, Election Fears, Fed Alone, Twitter

The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.

Jim Cramer: Abbott's Rapid Covid-19 Test and My Super Bowl Dreams

Jim Cramer: Abbott's Rapid Covid-19 Test and My Super Bowl Dreams

Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.

Jim Cramer: We're Feeling the Wrath of the Sellers - And It's About Time

Jim Cramer: We're Feeling the Wrath of the Sellers - And It's About Time

The greedy are, at last, getting blown out, and the prudent being vindicated. I see three buckets of stocks that intrigue me now.

Auction Action

The 10-year U.S. note auction was soft. The yield of 0.704% was above the when issued of about 0.695%. The bid to cover of 2.30 was below the 12 month average of 2.47. Also, dealers were left with 27% of the auction vs. the one year average of 25%. ...

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.

The Week Ahead, Markets Haven't Been Wrong, Closer to a Vaccine? Watching J&J

The Week Ahead, Markets Haven't Been Wrong, Closer to a Vaccine? Watching J&J

The equity market recovery is just as sloppy in performance as the economy itself.

The Nasdaq and Great Stock Picking Continue to Lead the Market Higher

The Nasdaq and Great Stock Picking Continue to Lead the Market Higher

If you're looking for some corrective action to gain momentum, then you will have to wait for broader selling.

Iconic Johnson & Johnson Is Poised for an Upside Breakout

Iconic Johnson & Johnson Is Poised for an Upside Breakout

Here's how we would trade the blue chip stock.

Emergent BioSolutions Could See Further Upside Gains

Emergent BioSolutions Could See Further Upside Gains

Most of the indicators are still bullish in this name, although some profit-taking may be occurring.

Jim Cramer: Betting Against Science Is a Mug's Game

Jim Cramer: Betting Against Science Is a Mug's Game

The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.

Jim Cramer: This Is Where to Put Your Cash as Covid Surges

Jim Cramer: This Is Where to Put Your Cash as Covid Surges

Instead of scratching your head and saying the market defies logic, look to the Cramer Covid-19 Index.

Big Tech's Big Night, Eyeing Amazon, My Kodak Moment, Powell's Blunt Assessment

Big Tech's Big Night, Eyeing Amazon, My Kodak Moment, Powell's Blunt Assessment

The Fed has done a lot, and is willing to do even more, but for now, is watching Congress. The fiscal side is where the next shoe falls.

Jim Cramer: I'm Sick of Hearing All This Nonsense About the Fed

Jim Cramer: I'm Sick of Hearing All This Nonsense About the Fed

Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Jim Cramer: Non-Traditional Banks Are Starting to Pull Away From the ETFs

Jim Cramer: Non-Traditional Banks Are Starting to Pull Away From the ETFs

Overall, the banks failed you again. But the future for two of them is much brighter than the past.

Take a Dare and Fly With This Dividend Stock

Take a Dare and Fly With This Dividend Stock

Eagle Financial is small bank name that goes under the radar of most investors, but it offers a 4% yield and boasts 34 years of increases.

Jim Cramer: 'Excuse Selling'

Jim Cramer: 'Excuse Selling'

Let's go over five excuses so you know and are armed with them when they are used and make you faint and weak-handed.

Jim Cramer: An Analyst's Dream

Jim Cramer: An Analyst's Dream

All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.

Johnson & Johnson Is Poised (Again) for an Upside Breakout

Johnson & Johnson Is Poised (Again) for an Upside Breakout

In this market, winning stocks 'stick out like a sore thumb.'

Jim Cramer: Here's My Sore Thumb Index

Jim Cramer: Here's My Sore Thumb Index

This is how you can tell which camp is winning and which is losing in this time of Covid-contradiction.

Where Health Meets Tech: 7 Testing and Diagnostics Stocks to Know

Where Health Meets Tech: 7 Testing and Diagnostics Stocks to Know

Experts pick their favorite long-term investments in medical diagnostics, testing and laboratory services.

Novavax and Its $1.6 Billion Award Just Got My Attention

Novavax and Its $1.6 Billion Award Just Got My Attention

The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.

Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers

Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers

What if the market is simply pricing in a quarter that had already been priced out?